Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SYS6090 alone and in combination in advanced driver-negative non-small cell lung cancer
CTR20263523Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Sep 2026; status: active.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263523.